Aviva Cdkn1A Elisa

Description: Description of target: May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex . Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: 1.95 pg/mL

Description: Description of target: Levonorgestrel is a synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.;Species reactivity: Pan-Species;Application: ;Assay info: Assay Methodology: Competitive Inhibition Immunoassay;Sensitivity: 0.53 ng/mL

Description: Description of target: Lumisterol is a steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result in ERGOCALCIFEROL.;Species reactivity: Pan-Species;Application: ;Assay info: Assay Methodology: Competitive Inhibition Immunoassay;Sensitivity: 2.19 ng/mL

Description: Description of target: Synthetic 9 residue cyclic peptide. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity.;Species reactivity: Pan-Species;Application: ;Assay info: Assay Methodology: Competitive Inhibition Immunoassay;Sensitivity: 5.27 pg/mL

Description: Description of target: cAMP is a second messenger, used for intracellular signal transduction, such as transferring into cells the effects of hormones like glucagon and adrenaline, which cannot pass through the cell membrane. It is involved in the activation of protein kinases and regulates the effects of adrenaline and glucagon. cAMP also binds to and regulates the function of ion channels such as the HCN channels and a few other cyclic nucleotide-binding proteins such as Epac1. cAMP is synthesised from ATP by adenylyl cyclase located on the inner side of the plasma membrane. Adenylyl cyclase is activated by a range of signaling molecules through the activation of adenylyl cyclase stimulatory G (Gs)-protein-coupled receptors and inhibited by agonists of adenylyl cyclase inhibitory G (Gi)-protein-coupled receptors. Liver adenylyl cyclase responds more strongly to glucagon, and muscle adenylyl cyclase responds more strongly to adrenaline. cAMP decomposition into AMP is catalyzed by the enzyme phosphodiesterase.;Species reactivity: All;Application: ;Assay info: Assay Methodology: Quantitative Competitive ELISA;Sensitivity: 0.096nmol/L

Description: Description of target: Pentosidine is a biomarker for advanced glycation endproducts, or AGEs. It is a well characterized and easily detected member of this large class of compounds.;Species reactivity: All;Application: ;Assay info: Assay Methodology: Quantitative Competitive ELISA;Sensitivity: 0.51 ng/mL

Description: Description of target: erum Cholygllycine (Cholygllycine, CG) is a combination of secondary bile acids with glycine conjugated bile acids, in liver cells, cholesterol, after its complex enzymatic reaction, turn into the primary bile acid. Cholic acid (CA) and chenodeoxycholic acid (the CD-CA). Bile acid steroid nucleus three hydroxyl groups (C3, C7, C12), the side chain hydroxyl at the end of the peptide bond and glycine combined with a molecular weight of 462u. CG normal metabolic pathways of the intestine - liver circulation, CG synthesized by hepatocytes, bile canaliculi, bile duct discharged into the gall bladder, along with the bile into the duodenum to help digestion of food. 95% of bile acid reabsorption in the distal ileum, come back to the liver via the portal vein, and uptake by the liver cells to re-use. Exist in the form of protein binding in serum, the total amount of overflow into the systemic circulation is less than 1%. Under normal circumstances, bile acid content in the peripheral blood, leaving little room for normal adults, whether fasting or postprandial serum CG concentration stabilized at a low level. When liver cells are damaged, the liver cell uptake CG capacity decreased, resulting in increased CG content in the blood; cholestasis, liver excretion of bile acids that barriers to reflux of blood circulation increased CG content, but also to the blood CG levels increased. Therefore, the determination of serum glycocholic acid (SCG) by ELISA method is a sensitive indicator to evaluate the function of liver cells and their hepatobiliary material circulation. Normal serum Cholygllycine: 1.3 ± 0.8mg / L, range 0.4 to 2.98mg / L, and the low limit of the hepatitis diagnosis <3.18mg / L ;Species reactivity: All;Application: ;Assay info: Assay Methodology: Quantitative Competitive ELISA;Sensitivity: 0.5 ng/mL

Description: Description of target: 5-Dehydroepiandrosterone (5-DHEA) is a 19-carbon endogenous steroid hormone. It is the major secretory steroidal product of the adrenal glands and is also produced by the gonads and the brain. DHEA is the most abundant circulating steroid in humans. DHEA has been implicated in a broad range of biological effects in humans and other mammals. It acts on the androgen receptor both directly and through its metabolites, which include androstenediol and androstenedione, which can undergo further conversion to produce the androgen testosterone and the estrogens, including estrone, estradiol, and estriol. DHEA is also a potent sigma-1 agonist. It is considered a neurosteroid. ;Species reactivity: All;Application: ;Assay info: Assay Methodology: Quantitative Competitive ELISA;Sensitivity: 0.091 ng/mL

Description: Mouse polyclonal to CDKN1A

Description: Mouse polyclonal to CDKN1A

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC;WB:1:1000-2000.IHC:1:100-200

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:5000, WB:1:200-1:1000, IHC:1:25-1:100

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:5000, WB:1:500-1:2000, IHC:1:15-1:50

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:1000-1:2000, IF:1:200-1:500

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB

Description: A polyclonal antibody against CDKN1A. Recognizes CDKN1A from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

Description: Mouse monoclonal to CDKN1A

Description: A cloning plasmid for the CDKN1A gene.